Impact of opioid overdoses on US life expectancy and years of life lost, by demographic group and stimulant co-involvement: a mortality data analysis from 2019-2021

Introduction

The opioid epidemic is an urgent public health issue in the United States. Fatal opioid overdoses in the US have increased more than tenfold since 1999, reaching 80,411 deaths in 2021.¹ The initial rise in opioid-related deaths was driven by prescription opioids, following aggressive marketing by the pharmaceutical industry.^2,3 A second wave, consisting of increasing heroin overdose deaths, emerged in 2010, followed in 2013 by a third wave involving synthetic opioids (primarily illicitly-manufactured fentanyl). Most recently, a fourth wave of polysubstance use has emerged, in which stimulants such as methamphetamines or cocaine are increasingly used in combination with opioids.⁴ This increased co-use of stimulants and opioids, associated with a higher risk of fatal overdose, is hypothesized to be driven by a combination of users’ desire for the combined effects of the substances and their pervasiveness in the drug supply.^5,6 Following the onset of the COVID-19 pandemic, fatal and non-fatal overdoses involving opioids and combinations of opioids and stimulants surged.^4,7 While in its initial waves the opioid crisis was portrayed as predominantly affecting white people, the demographics have shifted in recent years.⁸ Disproportionately affected by the fourth wave of polysubstance use, Black/African American and American Indian/Alaska Native people are now experiencing higher opioid-related mortality rates than white people.⁹

An estimated 7 million people in the US had opioid use disorder (OUD) in 2019.¹⁰ OUD includes addiction, increased tolerance, and withdrawal symptoms when use is stopped, and contributes to health and social problems. A study estimated that individuals with OUD had 10 times higher mortality than the general population, and experienced overdose death rates of about 8 per 1,000 person-years, in the years 2006-2014.¹¹ While effective medications exist for OUD, it is estimated that only 28% of people needing treatment receive it.¹² Treatment initiation and retention rates are even lower among racial and ethnic minorities, due to disparities in access and systemic biases in health care.⁸

Opioid overdose mortality rates are alarmingly high, but measures based on death counts alone do not fully capture the impact of this crisis as they do not account for the young age at which most opioid-related deaths occur, compared to other leading causes of death like heart disease, stroke, cancer, and COVID-19. Consequently, calculating the impact of opioid mortality on US life expectancy better accounts for the age-distribution of deaths. Similarly, years of life lost (YLL) estimates how many additional years individuals would have lived, had they not died prematurely from the cause in question.¹³ Previous studies have estimated the YLL to the opioid crisis, both nationwide and for various subpopulations,^14–18 and examined past impacts of opioid-related deaths on the US life expectancy at birth.¹⁹ However, the impact of this recent surge in opioid-related deaths on the US life expectancy has not been estimated. There are also no updated, comprehensive comparisons of YLL across race and ethnicity groups since the observed shifts in the demographics of the crisis and the onset of COVID-19, nor have the YLL to stimulant co-involvement been estimated.

In this study, we quantify the changes in opioid-related mortality in the years 2019, 2020 and 2021, coinciding with the onset of the COVID-19 pandemic. For each year, we estimate the reduction in the US population’s life expectancy at birth due to opioid overdose deaths, in addition to estimating the resulting years of life lost. We compare these metrics across demographic groups, highlighting which groups have seen the largest loss in life expectancy due to opioid-related mortality in the last few years. We also estimate the contributions of polysubstance use, both nationwide and by demographic group.

Methods

Results

Opioid overdose deaths in the United States have been on the rise nearly every year since the late 1990s, and have increased dramatically since 2019 (Suppl. Figure 1). From 2019 to 2020 there was a 38% increase in the number of opioid-related deaths, and from 2020 to 2021 a further 17% increase, reaching 80,411 deaths (24·7 per 100,000) in 2021 (Table 1). In 2021, men had a 2·4 times higher rate of opioid-related deaths than women. In all race/ethnicity groups, opioid overdose death rates increased substantially since 2019. In 2021, the highest death rates were amongst American Indian/Alaska Native (AI/AN) and Black/African American people, at 38·7 and 33·5 deaths per 100,000, respectively. The recent sharp increase in overdose deaths is primarily driven by synthetic opioids (mainly fentanyl),²² whose death rate nearly doubled from 2019 to 2021 (Suppl. Figure 1A). Polysubstance use also rose in this period, primarily of cocaine or psychostimulants with abuse potential, which include methamphetamines (from now on referred to as psychostimulants in this text). By 2021, opioid overdose death rates with co-involvement of psychostimulants or cocaine had increased to 6·7 and 5·9 deaths per 100,000, respectively.

In the years 2019-2021, most opioid overdose deaths occurred among young adults (Figure 1A). The median age of individuals dying of opioid overdoses was 40 years old for men, and 41 for women in 2021. Almost all ages experienced an increase in the number of deaths from 2019 to 2021. While the number of opioid-related deaths varies between sexes, the percentage of deaths involving opioids is consistently high, exceeding 20% at each age between 20-34 years for women, and between 23-39 years for men (Figure 1B). Polysubstance use also occurred across all adult ages. Death rates involving both psychostimulants and opioids were highest among young adults aged 30-40 years, especially among men, whereas cocaine coinvolvement death rates were more uniform across adults aged 30-60 years (Figure 1D).

• Download figure
• Open in new tab

Figure 1: Age distributions of opioid overdose deaths in the United States.

A) Age distribution of opioid overdose deaths by sex, in total numbers for each year 2019-2021, and B) the percentage of all deaths that are due to opioid overdoses at each age, by sex, for each year 2019-2021. C) the years of life lost to all opioid overdose deaths at each age, by sex, for each year 2019-2021. D) 2021 age distribution of opioid overdose death rates by sex and polysubstance use. In A), B), and C) the years 2019, 2020, and 2021 are shown in subsequently lighter colors. Note the similarity of the 2021, 2020 and 2019 distributions of % deaths in (B). In 2021 and 2020, despite the increase in the number of opioid overdose deaths, they represented a similar percentage of total deaths in the US due to additional COVID-19 deaths ²³.

The life expectancy at birth (LE) of the US population is considerably shortened due to the opioid crisis. We found that LE was reduced by 0·52 years in 2019, and 0·65 years in 2021 (Table 2) (see Methods). In 2021, almost half of this loss in LE was due to deaths also involving either cocaine or psychostimulants in addition to opioids. Subdividing by race and sex, we found all groups had a larger loss in LE in 2021 compared to 2019, except Asian women (Figure 2A, Suppl. Table 1). In this period, the loss in LE of Hispanic men and AI/AIN women doubled. In 2021, the LE of white and AI/AN men were reduced by 1 year, followed by Black men (0·96 years). The LE of AI/AN women was reduced by 0.90 years, followed by white and Black women (0·50 and 0·43 years, respectively).

• Download figure
• Open in new tab

Figure 2: Loss in life expectancy and years of life lost per capita in the US.

A) Loss in life expectancy and B) Years of life lost per capita due to opioid-related deaths for each sex and race/ethnicity group, for years 2019-2021. C) Years of life lost per capita due to opioid overdose deaths in 2021, by state, and D) relative increase in years of life lost per capita between 2019 and 2021, by state. Losses in life expectancy are estimated by comparing real life expectancies to estimated counterfactual life expectancies, describing a scenario in which opioid-related mortality is eliminated. Years of life lost are found by comparing age at death to the counterfactual remaining life expectancy at age of death.

Years of life lost (YLL) is a measure that incorporates both the number of people dying and the difference between their actual and expected age at death. We estimate that 3 million years of life were lost to opioid overdoses in the US in 2021 alone (Table 2). In total, 14% (374,000) more years of life were lost to opioids in 2021 compared to 2020, and 34% (671,000) more years were lost in 2020 than in 2019. We also found that on average in 2021, 37 years were lost with each opioid-related death. Most of the years of life lost are among younger adults (Figure 1D). The YLL per capita varies across race and ethnicity groups, but across groups men lost more years than women (Figure 2B, Suppl. Table 1). Amongst women, AI/AN women lost the most years per capita throughout the period (1,050 per 100,000 in 2021). In 2019, white men lost the most years per capita (947 per 100,000), however, by 2021, the years lost per capita among Black and AI/AN and white men were more similar (1,510, 1,350 and 1,340 per 100,000, respectively). Each year, Asian people lost the fewest years of life. Psychostimulants with abuse potential or cocaine used in combination with opioids contributed a large portion of the YLL, from 39% in 2019 to 46% in 2021 (Table 2). In 2019, cocaine was involved in more loss of life than psychostimulants, but by 2021 psychostimulants were the larger contributor.

There is high geographic variation in the severity of the opioid crisis across the United States. In 2021, 23 states lost more than 1,000 years of life per 100,000. West Virginia saw the most YLL per capita (2,400 years per 100,000), followed by Delaware and Tennessee (1,600 and 1,500 years per 100,000, respectively) (Figure 2C, Suppl. Table 3). In contrast, Hawaii, Nebraska, and South Dakota all lost ten times fewer years per capita than West Virginia (240, 230, and 190 YLL per capita). Between 2019 and 2021, the YLL doubled or more in 10 states, 4 of which are in the south (Figure 2D). The loss in life expectancy also varies, with 12 states losing more than 1y in 2021 (up to 1·7 years in West Virginia) and 17 states losing between 0·2-0·5 years (Suppl. Figure 3, Suppl. Table 4).

Polysubstance use was implicated in close to 50% of all opioid overdose deaths in 2021, a proportion that has been increasing since 2012 (Suppl. Figure 1D). However, the contribution of cocaine vs psychostimulants with abuse potential to the overall prevalence of polysubstance involvement differs substantially by demographic group and by state. In 2021, cocaine was involved in 48% of opioid-related deaths in Rhode Island vs 6% in Alaska, while psychostimulant co-involvement varied from 60% in Alaska to 4% in Maryland (Figure 3A, B). In general states with the highest cocaine co-involvement have the lowest psychostimulants coinvolvement, while total polysubstance involvement varied less (between 23-66% in all states and 40-60% in 35/50 states) (Suppl. Figure 3). We estimated that overall polysubstance use contributed to about half of the years lost and life expectancy reduction to opioid-related deaths across all racial/ethnic groups (Figure 3C, Table 2). Relative loss of life from psychostimulant co-use was highest amongst AI/AN people (43% and 35% of total YLL among AI/AN women and men, respectively), whereas cocaine co-use was highest among Black people (44% and 39% of YLL among Black women and men, respectively).

• Download figure
• Open in new tab

Figure 3: Polysubstance use with opioids in the US in 2021.

A) Percentage of opioid-related deaths in 2021 that also involved cocaine, by state. B) Percentage of opioid-related deaths in 2021 that also involved psychostimulants with abuse potential, by state. C) Percentage of the years of life lost to opioids in 2021 for which either cocaine or psychostimulants were also involved, by race/ethnicity and sex group. Psychostimulants here refers to psychostimulants with abuse potential, which include methamphetamines. States with suppressed counts for deaths involving opioids and cocaine (see Methods), for which we therefore cannot report percentage of co-use, are shaded in gray. “Psychostimulant co-use” includes any overdose deaths that involve opioids and psychostimulants, which may or may not also involve cocaine. “Cocaine co-use” includes any overdose deaths that involve opioids and cocaine, which may or may not also involve psychostimulants. “Overlap of cocaine and psychostimulant co-use” includes any deaths involving both categories of stimulants in addition to opioids.

Discussion

The opioid crisis in the United States has been intensifying over the last 25 years, reaching 80,411 opioid overdose deaths in 2021. In this study, we estimate the reduction in life expectancy at birth due to opioid-related mortality, each year from 2019 to 2021. Life expectancy in the US has been stagnating and then declining since 2015, dropping by 2·4 years from 2019-2021.²⁰ While this decline is due to a variety of factors, the opioid crisis is likely the largest contributor after COVID-19.²⁴ In this study, we estimate that in 2021 alone, the opioid crisis reduced the US population’s life expectancy (LE) at birth by 0·65 years, compared to 0·61 years in 2020 and 0·52 years in 2019. This surge in fatal opioid overdoses at the onset of the COVID-19 pandemic coincided with disruptions in access to treatment and harm reduction programs, and increased social isolation during lockdown periods.²⁵

The years of life lost to opioid overdoses highlights both the large number of deaths, and how many are among young people: opioid overdoses are a leading cause of death in young adults nationwide, causing more than 20% of all deaths in 20-39 year olds. We find the years of life lost (YLL) to opioids increased annually, from 2 million in 2019 to 3 million in 2021. On average in 2021, 37 years of life were lost per opioid-related death. While other leading causes of death result in more total YLL, the years lost per death are much lower: an estimated 15 years are lost per cancer death, 14 per stroke death, and 9 per COVID-19 death.^26–28

Using these metrics, we find substantial variations in the burden of opioid-related deaths across demographic groups. In 2019, white men, followed by Black/African American men had the highest burden of opioid overdose deaths. However, by 2021, American Indian/Alaska Native (AI/AN),Black, and white men were all losing the most years of life per capita, and experiencing the largest reduction in LE (almost 1 year). Amongst women, AI/AN women had the highest burden each year, with a loss in life expectancy of 0·9 years in 2021. AI/AN and Black people experienced the largest increases in burden over this time, with nearly double the years of life lost in 2021 compared to 2019. Our results display a rapidly-rising burden of opioid overdose deaths among people of color, and add to previous work finding that contrary to early beliefs and media portrayals, the opioid crisis is no longer simply a “rural white problem”. Now severely affecting people of all races and ethnicities, the opioid crisis will only be slowed if the effective, evidence-based treatments are equitably delivered to all.

Our results show a large increase in these metrics of opioid mortality burden in the US, compared to studies in earlier years of the opioid crisis. Previous studies found that in 2016, US life expectancy at age 15 was reduced by 0·36 years, and 1·7 million years of life lost to opioids.^18,19 Relative to these studies, we estimated that these metrics nearly doubled by 2021, in just five years. A recent study estimated 2·9 million years of life lost in the US in 2021 to unintentional opioid-related deaths alone by comparing age at death to 2019 life expectancy estimates.¹⁸ In contrast, for each year in our study period, we compared age at death to counterfactual life expectancy estimates for the same year. This allows us to quantify the impact of opioid-related mortality before and during the COVID-19 pandemic, given the backdrop of increases in other causes of death.

Metrics based solely on overdose deaths are not complete measures of burden, as there are many other impacts of this crisis. Individuals suffering from OUD have reduced quality of life and economic participation, and impact the lives of family and community members.^29,30 OUD is also associated with high mortality rates across major causes of death, such as from infection from bloodborne pathogens such as HIV and HCV, suggesting that the opioid crisis is responsible for additional deaths.³¹ Future work incorporating other metrics of burden such as nonfatal overdose hospitalization rates or elevated mortality rates from other causes may allow for a more complete picture.

This study is based on data extracted from death certificates, which brings some limitations. First, there are guidelines but no standardized process for determining and reporting the cause of death, which leaves room for biases and leads to probable undercounting of opioid overdose deaths.³² Secondly, due to misclassification of drug types involved in overdose deaths, there is likely underreporting of opioid overdose deaths, varying by state.³³ Additionally, racial misclassification, which varies across race/ethnicity groups, may add error to estimates of allcause and opioid-related mortality, in particular for people of color.³⁴ Another source of error in our estimates stems from the data suppression of low death counts (see Methods). While we minimize the effects of this suppression by redistributing the missing counts, this adds some uncertainty to our estimates, especially for small groups. Altogether, this leads us to conclude that we are likely underestimating the total YLL to opioid overdose mortality nationally, and that our estimates of smaller demographic groups’ opioid-related burden may have larger errors.

Our study focuses on opioid-driven mortality only in the US, which has the estimated highest per capita and absolute burden globally. However, a parallel opioid crisis unfolds in Canada ^35–37. The Public Health Agency of Canada estimates that from 2019 to 2021 there was a 113% increase in the rate of opioid-related deaths (10 to 21·3 per 100,000), compared to a 59% increase in the US over the same time period (15·5 to 24·7 per 100,000)³⁷. Less appreciated is that many other countries around the world are now experiencing rapidly rising rates of opioid overdose, and have recently seen increases in opioid prescribing mirroring that in the US in prior decades ^36,38. The Global Burden of Disease study - last updated in 2019 - estimated that 22 countries had opioid overdose death rates greater than 1/100,000, concentrated in Europe and Central/Western Asia ³⁹. Better quantification of recent changes in the international burden is needed, in addition to urgent policy responses to prevent escalation to levels of the US crisis.

Our study highlights the staggering burden of the US opioid crisis and its acceleration during the COVID-19 pandemic. The US urgently needs comprehensive policy responses that match the scope of this national public health emergency to save hundreds of thousands of lives in the next few years.^40,41 Our results suggest several areas of focus. Although opioid overdose death counts are themselves high, the disproportionate burden of these deaths on life expectancy and years of life lost is due to the high burden among younger adults. Opioid dependency most often starts during adolescence or young adulthood and policies that specifically focus on preventing and treating addiction in this age group are critical. Two of the populations currently experiencing the largest increases in opioid mortality burden and losing the most life expectancy - Black and AI/AN men - are also the two groups that experience the highest rates of incarceration in the US. Interventions are needed to better treat substance abuse in incarcerated and newly-released individuals. While medication-assisted treatment is imperative for the millions of Americans currently living with opioid use disorder and at risk of fatal overdose, the crisis is unlikely to turn around unless the underlying structural drivers of opioid use and so-called “deaths of despair” are addressed. The rapid increase in high-potency fentanyl over the past decade, and the more recent increase in polysubstance overdoses, suggests the important role of the supply chain of illicit drugs in the trajectory of the opioid crisis. Innovative domestic law enforcement and foreign policy approaches are needed to control the massive flow of opioids into the US and their distribution throughout the country. Finally, the acceleration of opioid overdose deaths during the COVID-19 years - after a few promising years of slowdown - demands that pandemic preparedness activities include efforts to avoid the breakdowns in social, economic, and health systems that drive increases in substance abuse. Social isolation, job loss, reduced access to health services, disproportionate levels of severe COVID-19 among Black, AI/AN and Hispanic communities, and supply chain disruptions are all implicated in increased opioid overdose deaths from 2020 onwards. Although major COVID-19 policies included important measures to facilitate OUD treatment, this approach was clearly not sufficient.